Boston Scientific to Acquire Penumbra for ~$14.5 Billion
Boston Scientific announced an agreement to acquire medical-device maker Penumbra for roughly $14.5 billion, expanding its presence in neurovascular and peripheral-vascular therapies.
What's Behind the Expansion?
Penumbra's thrombectomy and vascular portfolio complements Boston Scientific's lineup
Stroke and vascular-disease treatment is a high-growth med-device segment
Scale strengthens R&D, manufacturing, and commercial reach
Acquisition accelerates entry into adjacent high-value clinical categories
Consolidation among device makers pursues pipeline and distribution synergies
Impact Analysis
The ~$14.5 billion acquisition deepens Boston Scientific's position in fast-growing vascular and neurovascular markets. Integration tends to expand R&D and manufacturing roles in core franchises while consolidating overlapping commercial functions, shaping med-device employment across the combined company.